Cohen Jade, Pai Akila, Sullivan Timothy M, Alden Peter, Alexander Jason Q, Cragg Andrew, Manunga Jesse M, Stephenson Elliot J, Skeik Nedaa, Titus Jessica M
Minneapolis Heart Institute Foundation, Minneapolis, MN.
Minneapolis Heart Institute Foundation, Minneapolis, MN.
Ann Vasc Surg. 2017 Oct;44:59-66. doi: 10.1016/j.avsg.2017.04.045. Epub 2017 May 10.
Current recommendations suggest lifetime follow-up for endovascular aortic aneurysm repair (EVAR) patients to avoid consequences associated with endoleak and aneurysm enlargement. Follow-up compliance has been reported between 43% and 92%, with most single-center studies citing successful follow-up surveillance at less than 60%. We investigated follow-up completeness with a defined surveillance program and subsequent secondary intervention prevalence from a single center.
Our surveillance program notified patients of the need for follow-up imaging and surgeon review. Data were obtained from retrospective review of a prospective database, including operative and follow-up details, follow-up imaging completeness, endoleak incidence, and secondary intervention prevalence.
Five hundred seventeen patients received elective EVAR from 2005 to 2015. Surveillance was achieved in 425 (82.3%). Mean number of follow-up studies was 4.2 ± 2.9 and median time to first follow-up was 36 days. Four hundred forty-eight patients (86.7%) had freedom from intervention. Sixty-nine unique patients (13.3%) had 107 secondary interventions. Median time to first secondary intervention in 69 patients was 476 days. Mean number of imaging studies for secondary intervention patients was 6.1 ± 3.9, compared with mean 3.4 ± 2.3 for patients without (P < 0.001). Overall mortality was 24.6% (n = 127), including 32 deaths of unknown cause (6.2% overall) and 95 of non-EVAR-related causes (18.3%). No aneurysm-related deaths were reported.
Regular post-EVAR surveillance through a dedicated program resulted in a high rate of follow-up compliance, 13.3% rate of secondary intervention, and low aneurysm-related mortality. Careful lifetime surveillance remains important in long-term care following elective EVAR.
当前建议指出,对于接受血管腔内主动脉瘤修复术(EVAR)的患者应进行终身随访,以避免与内漏和动脉瘤扩大相关的后果。据报道,随访依从性在43%至92%之间,大多数单中心研究显示成功的随访监测率低于60%。我们通过一个明确的监测计划调查了来自单一中心的随访完整性以及随后的二次干预发生率。
我们的监测计划告知患者需要进行随访成像检查和外科医生复查。数据来自对前瞻性数据库的回顾性分析,包括手术和随访细节、随访成像完整性、内漏发生率和二次干预发生率。
2005年至2015年期间,517例患者接受了择期EVAR手术。425例(82.3%)实现了随访。随访研究的平均次数为4.2±2.9次,首次随访的中位时间为36天。448例患者(86.7%)无需进行干预。69例(13.3%)患者进行了107次二次干预。69例患者首次进行二次干预的中位时间为476天。二次干预患者的成像研究平均次数为6.1±3.9次,而未进行二次干预的患者平均次数为3.4±2.3次(P<0.001)。总死亡率为24.6%(n = 127),包括32例死因不明的死亡(占总数的6.2%)和95例非EVAR相关原因导致的死亡(占18.3%)。未报告与动脉瘤相关的死亡病例。
通过专门计划进行定期的EVAR术后监测,随访依从率较高,二次干预率为13.3%,且与动脉瘤相关的死亡率较低。在择期EVAR术后的长期护理中,仔细的终身监测仍然很重要。